Arcturus has two proprietary technologies that have the potential to solve the major hurdles in RNA medicine development. Our LUNAR™ lipid-mediated delivery and Unlocked Nucleomonomer Agent (UNA) Oligomer chemistry technology can be used together or separately to create the next-generation of safe, effective RNA medicines.
LUNAR allows systemic delivery of all types of RNA therapeutics to target tissues. UNA oligomers are more stable, more potent and less toxic than standard oligomers.
We use our technologies in house, and partner with industry leaders, to discover and develop RNA medicines that treat rare and orphan diseases.
March 11, 2018
Arcturus Therapeutics Announces Extraordinary General Meeting of Shareholders
March 9, 2018
Arcturus Therapeutics to Present at Bio Europe on March 13th
March 5, 2018
Arcturus Therapeutics Calls on Proposed Director Nominees to Respond to Constructive Board Outreach